JO3145B1 - مركبات مفيدة لتثبيط chk1 - Google Patents
مركبات مفيدة لتثبيط chk1Info
- Publication number
- JO3145B1 JO3145B1 JOP/2011/0323A JOP20110323A JO3145B1 JO 3145 B1 JO3145 B1 JO 3145B1 JO P20110323 A JOP20110323 A JO P20110323A JO 3145 B1 JO3145 B1 JO 3145B1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds useful
- inhibiting chk1
- chk1
- inhibiting
- useful
- Prior art date
Links
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 aminopyrazole compound Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 101150113535 chek1 gene Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41113710P | 2010-11-08 | 2010-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3145B1 true JO3145B1 (ar) | 2017-09-20 |
Family
ID=45044707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2011/0323A JO3145B1 (ar) | 2010-11-08 | 2011-10-27 | مركبات مفيدة لتثبيط chk1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9067920B2 (enExample) |
| EP (1) | EP2638033B1 (enExample) |
| JP (1) | JP5792316B2 (enExample) |
| KR (1) | KR101533166B1 (enExample) |
| CN (1) | CN103180311B (enExample) |
| AR (1) | AR083575A1 (enExample) |
| AU (1) | AU2011326230B2 (enExample) |
| BR (1) | BR112013010009B1 (enExample) |
| CA (1) | CA2816944C (enExample) |
| DK (1) | DK2638033T3 (enExample) |
| EA (1) | EA022096B1 (enExample) |
| ES (1) | ES2541414T3 (enExample) |
| HR (1) | HRP20150530T1 (enExample) |
| JO (1) | JO3145B1 (enExample) |
| ME (1) | ME02119B (enExample) |
| MX (1) | MX2013005181A (enExample) |
| PL (1) | PL2638033T3 (enExample) |
| PT (1) | PT2638033E (enExample) |
| RS (1) | RS54012B1 (enExample) |
| SI (1) | SI2638033T1 (enExample) |
| TW (1) | TWI501956B (enExample) |
| WO (1) | WO2012064548A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| HRP20220351T1 (hr) | 2016-02-04 | 2022-05-13 | Pharmaengine, Inc. | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| KR20230115988A (ko) | 2020-11-30 | 2023-08-03 | 스미토모 파마 가부시키가이샤 | 5-헤테로아릴-1h-피라졸-3-아민 유도체 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| JPWO2023120696A1 (enExample) * | 2021-12-24 | 2023-06-29 | ||
| JPWO2023229032A1 (enExample) * | 2022-05-27 | 2023-11-30 | ||
| AU2024255916A1 (en) * | 2023-04-14 | 2025-11-13 | Blueprint Medicines Corporation | Cdk2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06000933A (es) * | 2003-07-25 | 2006-03-30 | Pfizer | Compuestos de aminopirazol y uso como inhibidores de chk1. |
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| EA011671B1 (ru) * | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| CN101218229A (zh) * | 2005-05-05 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用 |
| EP1893607A4 (en) * | 2005-06-09 | 2010-07-21 | Merck Sharp & Dohme | CHECKPOINT KINASE INHIBITORS |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
-
2011
- 2011-10-27 AR ARP110103973A patent/AR083575A1/es active IP Right Grant
- 2011-10-27 JO JOP/2011/0323A patent/JO3145B1/ar active
- 2011-10-28 TW TW100139492A patent/TWI501956B/zh active
- 2011-11-01 WO PCT/US2011/058692 patent/WO2012064548A1/en not_active Ceased
- 2011-11-01 BR BR112013010009-5A patent/BR112013010009B1/pt active IP Right Grant
- 2011-11-01 PT PT117882639T patent/PT2638033E/pt unknown
- 2011-11-01 PL PL11788263T patent/PL2638033T3/pl unknown
- 2011-11-01 DK DK11788263T patent/DK2638033T3/en active
- 2011-11-01 ES ES11788263.9T patent/ES2541414T3/es active Active
- 2011-11-01 JP JP2013537756A patent/JP5792316B2/ja active Active
- 2011-11-01 EA EA201390499A patent/EA022096B1/ru not_active IP Right Cessation
- 2011-11-01 KR KR1020137011808A patent/KR101533166B1/ko active Active
- 2011-11-01 CA CA2816944A patent/CA2816944C/en active Active
- 2011-11-01 ME MEP-2015-69A patent/ME02119B/me unknown
- 2011-11-01 RS RS20150352A patent/RS54012B1/sr unknown
- 2011-11-01 AU AU2011326230A patent/AU2011326230B2/en active Active
- 2011-11-01 CN CN201180053779.8A patent/CN103180311B/zh active Active
- 2011-11-01 US US13/877,923 patent/US9067920B2/en active Active
- 2011-11-01 MX MX2013005181A patent/MX2013005181A/es active IP Right Grant
- 2011-11-01 HR HRP20150530TT patent/HRP20150530T1/hr unknown
- 2011-11-01 EP EP11788263.9A patent/EP2638033B1/en active Active
- 2011-11-01 SI SI201130467T patent/SI2638033T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA022096B1 (ru) | 2015-10-30 |
| CA2816944C (en) | 2015-12-22 |
| EP2638033A1 (en) | 2013-09-18 |
| CN103180311B (zh) | 2014-08-20 |
| BR112013010009A2 (pt) | 2020-09-29 |
| MX2013005181A (es) | 2013-10-17 |
| RS54012B1 (sr) | 2015-10-30 |
| CN103180311A (zh) | 2013-06-26 |
| AU2011326230B2 (en) | 2015-02-19 |
| HRP20150530T1 (hr) | 2015-06-19 |
| EA201390499A1 (ru) | 2013-08-30 |
| US9067920B2 (en) | 2015-06-30 |
| PT2638033E (pt) | 2015-06-01 |
| AR083575A1 (es) | 2013-03-06 |
| KR101533166B1 (ko) | 2015-07-01 |
| WO2012064548A1 (en) | 2012-05-18 |
| BR112013010009B1 (pt) | 2021-10-19 |
| TWI501956B (zh) | 2015-10-01 |
| KR20130099146A (ko) | 2013-09-05 |
| ME02119B (me) | 2015-10-20 |
| CA2816944A1 (en) | 2012-05-18 |
| US20130190262A1 (en) | 2013-07-25 |
| AU2011326230A1 (en) | 2013-05-09 |
| JP2013541586A (ja) | 2013-11-14 |
| DK2638033T3 (en) | 2015-04-27 |
| PL2638033T3 (pl) | 2015-09-30 |
| ES2541414T3 (es) | 2015-07-20 |
| EP2638033B1 (en) | 2015-04-08 |
| JP5792316B2 (ja) | 2015-10-07 |
| TW201305138A (zh) | 2013-02-01 |
| SI2638033T1 (sl) | 2015-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2886B1 (en) | Useful compounds in the inhibition of CHK1 | |
| MX2013011330A (es) | Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso. | |
| JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MY184303A (en) | Notch pathway signaling inhibitor compound | |
| TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| UA98141C2 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| IN2014DN10670A (enExample) | ||
| MY181898A (en) | Heterocyclic compounds and uses thereof | |
| MX338327B (es) | Inhibidores de cdk. | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX2015007053A (es) | Compuestos dimericos. | |
| EA201492104A1 (ru) | Ингибитор jak1/2 | |
| MX2015007940A (es) | Compuestos tricíclicos como inhibidores de cftr. | |
| PH12015500399A1 (en) | Azaindolines | |
| MX2013015357A (es) | Terapia de combinacion. | |
| MX2015007054A (es) | Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso. | |
| TN2013000515A1 (en) | Notch pathway signaling inhibitor compound | |
| UA110834C2 (uk) | Сполука-інгібітор сигнального шляху notch | |
| CY1116362T1 (el) | Ενωσεις χρησιμες στην αναστολη της chk1 | |
| TN2011000013A1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
| TN2011000545A1 (en) | Vinyl indazolyl compounds | |
| UA101379C2 (en) | Amidophenoxyindazoles useful in the treatment of cancer |